Does CVS–Aetna Spell the End of Business as Usual?

The proposed $70 billion deal between CVS and Aetna would be a vertical merger that could heighten competition. By offering a new value proposition, the new company would aim to stay relevant despite encroachment by e-tailers and reduce total spending for care.

Podrobná bibliografia

Vydané v:	The New England journal of medicine Ročník 378; číslo 7; s. 593 - 595
Hlavný autor:	Dafny, Leemore S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Massachusetts Medical Society 15.02.2018
Predmet:	Acquisitions & mergers Antitrust Drug stores Health care policy Market shares Pharmaceutical industry Pharmacy Prescription drugs Primary care
ISSN:	0028-4793, 1533-4406, 1533-4406
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!